Anle138b-P1-02: A Randomised, Double-blinded, Placebo-controlled Phase 1b Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oligomer Modulator Anle138b in Parkinson′s Disease-MedSci.cn

Anle138b-P1-02: A Randomised, Double-blinded, Placebo-controlled Phase 1b Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oligomer Modulator Anle138b in Parkinson′s Disease

Levin, J; Singh, N; Melbourne, S; Morgan, A; Carroll, C; Fietzek, U; Ryazanov, S; Leonov, A; Griesinger, CH; Schmidt, F; Weckbecker, D; Prager, K; Matthias, T; Giese, A

MOVEMENT DISORDERS, 2023; 38 (): S37

科室
- - 订阅+
  - 更多科室
工具
服务